Novel treatment options for infectious exacerbations

Drug Discovery Today

Volumn 10, Issue 22, 2005, Pages 1500-1502

  Del Vecchio, Fred ^a   Mbow, Lamine ^a   Sarisky, Robert T ^a  

^a Infectious Diseases Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN DERIVATIVE; MACROLIDE; PREDNISONE; STEROID; TOLL LIKE RECEPTOR;

ANTIBIOTIC THERAPY; ASTHMA; BRONCHIECTASIS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC LUNG DISEASE; CYSTIC FIBROSIS; DISEASE EXACERBATION; HUMAN; INFECTION; INFLAMMATORY DISEASE; LOWER RESPIRATORY TRACT INFECTION; MYCOPLASMA PNEUMONIAE; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SHORT SURVEY; STEROID THERAPY; TREATMENT OUTCOME;

ASTHMA; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; MACROLIDES; RESPIRATORY TRACT INFECTIONS; TOLL-LIKE RECEPTORS;

EID: 27344440153     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03597-X     Document Type: Short Survey

References (17)

1. Weinberger M. Respiratory infections and asthma: current treatment strategies Drug Discov. Today 9 2004 831 837
2. Champney W.S. Macrolide antibiotics inhibit 50S ribosomal subunit assembly in Bacillus subtilis and Staphylococcus aureus Antimicrob. Agents Chemother. 39 1995 2141 2144
3. Shryock T.R. The effects of macrolides on the expression of bacterial virulence mechanisms J. Antimicrob. Chemother. 41 1998 505 512
4. Tamaoki J. Erythromycin inhibits CI secretion across canine tracheal epithelial cells Eur. Respir. J. 5 1992 234 238
5. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis J. Antimicrob. Chemother. 54 2004 21 28
6. Gemmell C.G. Effects of low concentrations of antibiotics on bacterial ultrastructure, virulence and susceptibility to immunodefences: clinical significance Lorian V. Antibiotics in Laboratory Medicine 4th edn 1996 Williams & Wilkins 397 452
7. Greos L.S. Macrolide antibiotics inhibit neutrophil chemotaxis J. Allergy Clin. Immunol. 85 1990 195
8. Amayasu H. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma Ann. Allergy Asthma Immunol. 84 2000 594 598
9. Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective Am. J. Med. 117 2004 2S 4S
10. Kikuchi T. Clarithroymycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NK-kappa B transcription factors J. Antimicrob. Chemother. 49 2002 745 755
11. Scaglione F. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin J. Antimicrob. Chemother. 41 1998 47 50
12. Garey K.W. Long-term clarithromycin treatment decreases prednisone requirements in elderly patients with prednisone-dependent asthma Chest 118 2000 1826 1827
13. Desaki M. Molecular mechanisms of anti-inflammatory action of erythromycin in human bronchial epithelial cells: possible role in the signaling pathway that regulates nuclear factor-kB activation Antimicrob. Agents Chemother. 48 2004 1581 1585
14. Lanza L. Possible differences in the mechanism(s) of action of different glucocorticoid hormone compounds Ann. N. Y. Acad. Sci. 876 1999 193 197
15. Barton G.M. Toll-like receptor signaling pathways. Science 300 2003 1524 1525
16. Park J.Y. Macrolide-affected Toll-like receptor 4 expression from Helicobacter pylori-infected monocytes does not modify interleukin-8 production FEMS Immunol. Med. Microbiol. 44 2005 171 176
17. Lien E., Ingalls R.R. Toll-like receptors Crit. Care Med. 30 2002 s1 s11